News
- Author:
- Neil Osterweil
Publish date: March 12, 2019
SAN FRANCISCO – Patients who had received antibiotics more than a month before a checkpoint inhibitor had significantly worse survival, regardless ...
News
- Author:
- Neil Osterweil
Publish date: March 12, 2019
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
News
- Author:
- Neil Osterweil
Publish date: March 11, 2019
SAN FRANCISCO – Early objective responses were sufficient to prompt a larger phase 3 trial of the TKI and immune checkpoint inhibitor combination.<...
News
- Author:
- Neil Osterweil
Publish date: March 7, 2019
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of nivoluma...
News
- Author:
- Neil Osterweil
Publish date: March 4, 2019
There were no differences in disease-free or overall survival or distant recurrence-free interval between regimens with or without epirubicin.
News
- Author:
- Neil Osterweil
Publish date: March 3, 2019
SAN FRANCISCO – Pulmonary sarcomatoid carcinoma tumors have high mutational burden and PD-L1 expression, making them ideal targets for immune check...
News
- Author:
- Neil Osterweil
Publish date: March 1, 2019
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous thromboemb...
News
- Author:
- Neil Osterweil
Publish date: February 20, 2019
An antibody-drug conjugate induced clinical responses in one third of patients with heavily pretreated metastatic triple-negative breast cancer.
News
- Author:
- Neil Osterweil
Publish date: February 13, 2019
Patients with both Merkel cell carcinoma subtypes had significantly better survival with first-line pembrolizumab, compared with historical control...
News
- Author:
- Neil Osterweil
Publish date: February 12, 2019
Shorter chemotherapy cycles and sequential dosing were associated with lower recurrence rates and better breast cancer-specific survival.
News
- Author:
- Neil Osterweil
Publish date: February 9, 2019
The thrombopoietin-receptor agonist was associated with worse outcomes, compared with placebo, during induction therapy for adults with AML.
News
- Author:
- Neil Osterweil
Publish date: February 8, 2019
A less intensive transplant and maintenance strategy proved equally effective as more aggressive approaches in patients with multiple myeloma.
News
- Author:
- Neil Osterweil
Publish date: February 8, 2019
WASHINGTON – Androgen deprivation therapy improves survival for men with high-risk cancers, but those with comorbid cardiovascular disease may be h...
News
- Author:
- Neil Osterweil
Publish date: February 7, 2019
WASHINGTON – Anthracycline-based chemotherapy, anti-HER2 agents, and radiation all increase the risk for subsequent heart disease in breast cancer ...
News
- Author:
- Neil Osterweil
Publish date: February 5, 2019
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and circulat...
